Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.
作者信息
Davido Benjamin, Fellous Lesly, Lawrence Christine, Maxime Virginie, Rottman Martin, Dinh Aurélien
机构信息
Maladies Infectieuses, Hôpital Universitaire Raymond-Poincaré, AP-HP, Garches, France
Pharmacie, Hôpital Universitaire Raymond-Poincaré, AP-HP, Garches, France.
出版信息
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.01008-17. Print 2017 Sep.
Abstract
摘要
相似文献
1
Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.头孢他啶-阿维巴坦与氨曲南：克服肠杆菌科细菌和铜绿假单胞菌中金属β-内酰胺酶介导的β-内酰胺耐药性的有趣策略
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.01008-17. Print 2017 Sep.
2
Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.头孢他啶-阿维巴坦联合氨曲南对产丝氨酸和金属β-内酰胺酶铜绿假单胞菌的活性。
Diagn Microbiol Infect Dis. 2021 Jan;99(1):115227. doi: 10.1016/j.diagmicrobio.2020.115227. Epub 2020 Sep 28.
3
Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens.头孢他啶-阿维巴坦与氨曲南对产丝氨酸和金属β-内酰胺酶的革兰氏阴性病原体的协同活性。
Diagn Microbiol Infect Dis. 2017 Aug;88(4):352-354. doi: 10.1016/j.diagmicrobio.2017.05.009. Epub 2017 May 18.
4
Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.治疗除肺炎克雷伯菌以外的耐药菌的头孢他啶/阿维巴坦的临床经验。
Int J Antimicrob Agents. 2018 Apr;51(4):629-635. doi: 10.1016/j.ijantimicag.2018.01.016. Epub 2018 Feb 2.
5
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.多中心评估头孢他啶-阿维巴坦和头孢洛扎坦-他唑巴坦对血液、呼吸道和伤口来源的美罗培南不敏感铜绿假单胞菌的抑制活性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00875-17. Print 2017 Oct.
6
Successful Treatment of Bacteremia Due to NDM-1-Producing with Aztreonam and Ceftazidime-Avibactam Combination in a Pediatric Patient with Hematologic Malignancy.在一名患有血液系统恶性肿瘤的儿科患者中，使用氨曲南和头孢他啶-阿维巴坦联合治疗成功治愈了由产NDM-1菌株引起的菌血症。
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.02463-18. Print 2019 Feb.
7
Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.头孢他啶/阿维巴坦与氨曲南联合治疗产NDM-1/OXA-48/CTX-M-15肺炎克雷伯菌感染后的临床结局
J Antimicrob Chemother. 2018 Apr 1;73(4):1104-1106. doi: 10.1093/jac/dkx496.
8
Management of serious infections caused by metallo β-lactamases with or without OXA-48-like expressing Enterobacterales with aztreonam and ceftazidime/avibactam combination: Dosing strategy for better clinical outcome.使用氨曲南和头孢他啶/阿维巴坦联合治疗由产金属β-内酰胺酶（无论是否伴有产OXA-48样酶的肠杆菌科细菌）引起的严重感染：为获得更好临床结局的给药策略
Indian J Med Microbiol. 2021 Jul;39(3):286-288. doi: 10.1016/j.ijmmb.2021.04.002. Epub 2021 Apr 21.
9
In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017.2015-2017 年 18 个欧洲国家分离的革兰氏阴性菌对头孢他啶-阿维巴坦的体外活性。
Int J Antimicrob Agents. 2020 Sep;56(3):106045. doi: 10.1016/j.ijantimicag.2020.106045. Epub 2020 Jun 6.
10
The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.头孢他啶、头孢洛林和氨曲南与阿维巴坦联合应用对目标革兰氏阴性菌的抗生素后效应及β-内酰胺酶抑制剂后效应
Lett Appl Microbiol. 2016 Aug;63(2):96-102. doi: 10.1111/lam.12592.
引用本文的文献
1
Ceftazidime-Avibactam Plus Aztreonam for the Treatment of Blood Stream Infection Caused by Resistant to All Beta-Lactame/Beta-Lactamase Inhibitor Combinations.头孢他啶-阿维巴坦联合氨曲南治疗对所有β-内酰胺类/β-内酰胺酶抑制剂组合耐药的血流感染
Antibiotics (Basel). 2025 Aug 7;14(8):806. doi: 10.3390/antibiotics14080806.
2
Antimicrobial Susceptibility Testing of the Combination of Aztreonam and Avibactam in NDM-Producing : A Comparative Evaluation Using the CLSI and EUCAST Methods.氨曲南与阿维巴坦联合用于产NDM菌株的抗菌药物敏感性试验：采用CLSI和EUCAST方法的比较评估
Antibiotics (Basel). 2025 Jul 3;14(7):675. doi: 10.3390/antibiotics14070675.
3
A comparative analysis of clinical outcomes in hematological patients afflicted with bacteremia attributable to carbapenem-resistant versus .耐碳青霉烯类所致菌血症血液病患者临床结局的比较分析 与……相对比 （原文此处不完整）
Front Cell Infect Microbiol. 2025 Jun 17;15:1600746. doi: 10.3389/fcimb.2025.1600746. eCollection 2025.
4
[In vitro activity of ceftazidime- avibactam and ceftolozane- tazobactam against clinical isolates of enterobacteriaceae and : results from a trauma center and burn unit in tunisia].[头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对突尼斯一家创伤中心和烧伤科肠杆菌科临床分离株的体外活性：结果]
Ann Burns Fire Disasters. 2025 Mar 31;38(1):31-37. eCollection 2025 Mar.
5
Study on the invitro synergistic susceptibility and biofilm inhibition mechanism of ceftazidime-avibactam combined with aztreonam against carbapenem-resistant .头孢他啶-阿维巴坦联合氨曲南对耐碳青霉烯类细菌的体外协同敏感性及生物膜抑制机制研究
Front Microbiol. 2025 Mar 20;16:1542029. doi: 10.3389/fmicb.2025.1542029. eCollection 2025.
6
Use of MALDI-TOF VITEK MS for rapid and efficient identification of KPC-type carbapenemases in Enterobacterales carrying the Tn4401a transposon.使用基质辅助激光解吸电离飞行时间质谱仪（MALDI-TOF VITEK MS）快速高效鉴定携带Tn4401a转座子的肠杆菌科细菌中的KPC型碳青霉烯酶。
Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1443-1453. doi: 10.1007/s10096-025-05097-6. Epub 2025 Apr 3.
7
Combined therapeutic option for NDM-producing Serratia Marcescens - an in vitro study from clinical samples.产NDM的粘质沙雷氏菌的联合治疗方案——一项来自临床样本的体外研究
Braz J Infect Dis. 2025 Jan-Feb;29(1):104481. doi: 10.1016/j.bjid.2024.104481. Epub 2024 Nov 26.
8
Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens.阿曲南-阿维巴坦：对抗多重耐药革兰氏阴性病原体的活力组合。
Pharmacotherapy. 2024 Dec;44(12):927-938. doi: 10.1002/phar.4629. Epub 2024 Nov 27.
9
Practical Application of Aztreonam-Avibactam as a Treatment Strategy for Ambler Class B Metallo-β-Lactamase Producing Enterobacteriaceae.氨曲南-阿维巴坦作为治疗产Ambler B类金属β-内酰胺酶肠杆菌科细菌的治疗策略的实际应用。
Antibiotics (Basel). 2024 Aug 14;13(8):766. doi: 10.3390/antibiotics13080766.
10
Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli.多中心评价阿兹提罗单抗与阿维巴坦、雷利巴坦和沃巴坦联合用于治疗产金属β-内酰胺酶的碳青霉烯类耐药革兰氏阴性杆菌的活性。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0069324. doi: 10.1128/aac.00693-24. Epub 2024 Aug 19.
本文引用的文献
1
Discordance with Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model.与活性的不一致：在小鼠肺部感染模型中，头孢他啶-阿维巴坦、氨曲南和替加环素单独及联合使用对产新德里金属β-内酰胺酶的肺炎克雷伯菌的人源化暴露情况。
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00486-17. Print 2017 Jul.
2
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?头孢他啶-阿维巴坦和氨曲南能否克服肠杆菌科细菌中金属β-内酰胺酶介导的β-内酰胺耐药性？
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.
3
Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.住院时分离的三代头孢菌素耐药肠杆菌科细菌对头孢菌素联合制剂和阿维巴坦/氨曲南的敏感性。
Int J Antimicrob Agents. 2017 Feb;49(2):239-242. doi: 10.1016/j.ijantimicag.2016.10.013. Epub 2016 Nov 28.
Zotero 插件